TRAW logo

TRAWS PHARMA INC

TRAWNASDAQ
๐Ÿ† #5038 by market capEarnings Apr 13 ยท PostUS Equity
$0.18โ–ผ $0.05 (โˆ’23.91%)
Market closed ยท at close
๐Ÿ””
Track TRAW
Get earnings, price moves & breaking news on Telegram
Track
24hโ–ผ 23.9%
7dโ–ผ 32.7%
14dโ–ผ 23.9%
30dโ–ผ 48.8%
ytdโ–ผ 84.1%
1yโ–ผ 92.4%
๐ŸฆMarket Cap
$3M
Small Cap
๐Ÿ“ˆRevenue Growth (YoY)
โ€”
๐Ÿ“ŠGross Margin
โ€”
๐Ÿ’ตFCF Margin
โ€”
โš–๏ธP/S Ratio
1.2x
Cheap
Otter Score
โ€”
Insufficient data

Trading Snapshot

Day Range
$0.17 โ€“ $0.22
52-Week Range
$0.22 โ€“ $3.23
Volume (shares)
381,987
Avg Volume (shares)
โ€”
Shares Outstanding
15.4M
Next Earnings
2027-04-13

Fundamentals Snapshot

Annual Revenue
$3M
Last Q Revenue
โ€”
P/E Ratio
โ€”
P/S Ratio
1.2x
EPS (TTM)
$-2.11
Dividend Yield
โ€”
Dilution (1yr)
+771.1%
TRAW logo

TRAWS PHARMA INC

TRAW
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$3Mโ–ฒ +1134.5% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
100.0%โ–ฒ +5.6% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isnโ€™t profitable yet.
โˆ’$18Mโ–ผ โˆ’63.8% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
โˆ’$21Mโ–ผ โˆ’30.3% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing ownerโ€™s slice.
8.4Mโ–ฒ +771.1% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$4Mโ–ผ โˆ’$18M YoY
StockOtter ยท stockotter.space

About TRAWS PHARMA INC

Traws Pharma, Inc., a biopharmaceutical firm in the clinical development stage, is dedicated to creating novel small-molecule medications delivered orally to combat both respiratory viral infections and various forms of cancer. Its pipeline includes experimental treatments specifically designed to overcome drug resistance in influenza and COVID-19. These promising candidates include TRX01 (travatrelvir), an Mpro/3CL inhibitor currently undergoing development for COVID-19, and TRX100 (viroxavir), an endonuclease inhibitor advancing through trials for pandemic influenza. Additionally, Traws Pharma's oncology portfolio features narazaciclib, a multi-kinase CDK4/6 inhibitor. This compound is presently in Phase 1/2 clinical trials in cancer patients, being evaluated both independently and in conjunction with letrozole, with the goal of establishing the recommended Phase 2 dosage for future work in endometrial cancer. The company is also investigating oral rigosertib, exploring its potential as a standalone therapy or in combination regimens across diverse cancer types. Originally established in 1998 as Onconova Therapeutics, Inc., the company officially adopted its current name, Traws Pharma, Inc., in April 2024. Its corporate headquarters are located in Newtown, Pennsylvania.

๐Ÿฆฆ

Otter Score Breakdown

How it's scoredFive components, each rated 1โ€“5โ˜… and equally weighted (20%), averaged to a 0โ€“100 score:๐Ÿ’Ž Quality โ€” gross margin๐Ÿš€ Growth โ€” revenue YoYโš–๏ธ Valuation โ€” P/S ratioโšก Momentum โ€” 30-day price change๐Ÿ’ง Dilution โ€” 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

โš–๏ธValuationโ˜…โ˜…โ˜…โ˜…โ˜…
๐Ÿ’งDilutionโ˜…โ˜…โ˜…โ˜…โ˜…
Overall Score
Insufficient data
โ€”/100

Analyst Ratings

โ“˜
Consensus
Sell
7 analysts
Strong Buy0
Buy0
Hold4
Sell1
Strong Sell2
Ratings as of Nov 2026

Latest News & Updates